- Home
- BITF vs ANAB Comparison
BITF vs ANAB Comparison
Compare BITF & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BITF | ANAB |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BITF | ANAB |
|---|---|---|
| Price | $2.05 | $65.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $4.00 | ★ $72.60 |
| AVG Volume (30 Days) | ★ 28.4M | 485.8K |
| Earning Date | 05-13-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $44.56 | N/A |
| Revenue Next Year | N/A | $33.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $0.68 | $15.40 |
| 52 Week High | $6.60 | $68.39 |
Technical Indicators
Market Signals| Indicator | BITF | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 61.87 |
| Support Level | $1.94 | $43.67 |
| Resistance Level | $2.40 | $68.39 |
| Average True Range (ATR) | 0.17 | 3.23 |
| MACD | -0.00 | -0.17 |
| Stochastic Oscillator | 7.82 | 73.04 |
Price Performance
Historical ComparisonAbout BITF Bitfarms Ltd.
Bitfarms Ltd engaged in the cryptocurrency Mining industry mainly consists of selling its computational power used for hashing calculations for cryptocurrency mining in multiple jurisdictions. Its geographic operations are currently located in Canada, the United States, Argentina. It owns and operates server farms comprised of computers designed to validate transactions on the Bitcoin Blockchain.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).